Amanda Glassman
Executive Vice President of CGD, CEO of CGD Europe, and Senior Fellow
Topics:
Governments and Development, Corruption, Transparency, and Governance, Gender and Equality, Latin America Initiative, Development Impact Bonds, Population and Development Research Agenda, Global Health, Achieving More Health for the Money, iDSI and Priority-Setting, Health Benefits Packages, Better Fiscal Policy for Health, Evaluating Health Programs, Millions Saved, Family Planning, Global Health Innovation and Access: Sustainable Business Models, The Future of Global Health Procurement, Vaccines, Global Health Security, Coronavirus Preparedness & Response, Antimicrobial Resistance, Global Health Policy Research Network
Expertise
Health financing and payment, results-based financing, social protection, conditional cash transfer programs, noncommunicable disease, maternal and child health
Bio
Amanda Glassman is executive vice president and senior fellow at the Center for Global Development and also serves as chief executive officer of CGD Europe. Her research focuses on priority-setting, resource allocation and value for money in global health, as well as data for development. Prior to her current position, she served as director for global health policy at the Center from 2010 to 2016, and has more than 25 years of experience working on health and social protection policy and programs in Latin America and elsewhere in the developing world.
Prior to joining CGD, Glassman was principal technical lead for health at the Inter-American Development Bank, where she led policy dialogue with member countries, designed the results-based grant program Salud Mesoamerica 2015 and served as team leader for conditional cash transfer programs such as Mexico’s Oportunidades and Colombia’s Familias en Accion. From 2005-2007, Glassman was deputy director of the Global Health Financing Initiative at Brookings and carried out policy research on aid effectiveness and domestic financing issues in the health sector in low-income countries. Before joining the Brookings Institution, Glassman designed, supervised and evaluated health and social protection loans at the Inter-American Development Bank and worked as a Population Reference Bureau Fellow at the US Agency for International Development. Glassman holds a MSc from the Harvard School of Public Health and a BA from Brown University, has published on a wide range of health and social protection finance and policy topics, and is editor and coauthor of the books What's In, What's Out: Designing Benefits for Universal Health Coverage (Center for Global Development, 2017), Millions Saved: New Cases of Proven Success in Global Health (Center for Global Development 2016), From Few to Many: A Decade of Health Insurance Expansion in Colombia (IDB and Brookings 2010), and The Health of Women in Latin America and the Caribbean (World Bank 2001).
Media Contact
Sean Bartlett
sbartlett@cgdev.org
Featured Work
In the News
Working Groups
High-res photo
More From Amanda Glassman
April 30, 2014
Blog Post
This is the first blog in a series of two. Read the second here. This is a joint post with Miriam Temin. Miriam is coordinating editor for the new edition of Millions Saved.
After a comprehensive literature review, expert consultations, public calls for proposals, and advisory group meetings, we’ve mostly decided on a short list of cases for the new edition of Millions Saved—a book of case studies that document global health successes at scale. Selected interventions range from helmet laws to universal health coverage programs—but one of the most well-known global health efforts of the last decade, malaria control, hasn’t made our list -- at least not yet (for more on what did make the list, check back here in the coming months).
April 3, 2014
Publication
The US has an untapped opportunity to offer global leadership against drug resistance through the major global health programs it already supports, namely PEPFAR, the Global Fund, and the Presidents Malaria Imitative. In this memo, Victoria Fan and Amanda Glassman highlight considerations for Congress with respect to oversight of these key channels of US development assistance for health that greatly affect drug resistance.
March 31, 2014
Blog Post
Amanda Glassman discusses the need for a new institution to support low- and middle-income governments and donors in resource allocation decisions for health care.
March 25, 2014
Blog Post
Successful investments in global health—or “best buys”— can be defined in many ways: a cost-effective commodity or technology, a well-trained health workforce, an evidence-informed policy, etc. We recently hosted an event in partnership with PSI, PATH, Devex, and Merck to discuss this topic, and noted a reoccurring theme: service delivery is key.
Pages
May 17, 2013
Blog Post
The Global Fund to Fight AIDS, TB and Malaria recently made it easier to find out where their money is going with the launch of a new, online grant portfolio portal. This welcome and timely tool comes amid the Global Fund’s ambitious replenishment process that asks donors for $15 billion over the next three years to fight HIV/AIDS, TB and malaria – a considerable amount that totals twice the Fund’s average annual disbursements over the past decade. So we’re pleased to see the Global Fund take such a significant step to show stakeholders how these investments are being spent and what they are achieving. And as avid users of Global Fund data ourselves, we’re particularly pleased to see a few features of this new tool:
November 12, 2012
Blog Post
This week the Global Fund Board will determine whether to “expand, accelerate, terminate or suspend the Affordable Medicines Facility – malaria (AMFm).” Ideally, the Board would make an evidence-based decision. However, both the sufficiency and the relevance of available technical evidence have been questioned (see here and here). The role of political and process evidence is also not very transparent. Below, we lay out our understanding of the potential options and the factors the Board should consider.
November 8, 2012
Blog Post
This is a joint post with Heather Lanthorn.
The Global Fund Board’s decision over the Affordable Medicines Facility – malaria (AMFm) rapidly approaches, and tensions within the malaria community are acute. In her global health blog for The Guardian, Sarah Boseley characterizes the rift as one of
“huge arguments and intense passions…[because] it is about the belief on one side that the private sector is the most effective way to get medicines to those who need them – and the certainty on the other side that bolstering the public sector to diagnose and treat people is a fairer and safer way to go. These are not just practical matters, but highly political.”
April 19, 2012
Blog Post
This week the World Health Organization made dementia a priority, while Jim Kim—next in line for the World Bank—chose his as job creation. “Priority” is a word that is often used in global health and development when calling for increased attention to or funding of specific diseases, services, or interventions. But when facing a limited budget (as most low- and middle-income countries are) how can countries best sort multiple priorities into effective, sustainable policies?
Commentary Menu